Insilico Medicine Mediaroom - PR Newswire APAC

Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

The paper introduces three interconnected resources for the global scientific community: * Longe...

2026-09-17 23:21 2936

Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks

* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed wi...

2026-09-07 17:42 2342

Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain

CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clini...

2026-09-03 08:30 2733

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clini...

2026-08-17 20:30 4245

Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clini...

2026-08-12 20:30 2560

Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates

CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clini...

2026-08-11 17:45 2542

Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science

Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a...

2026-07-30 21:00 3041

Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma

* FDA Fast Track Designation (FTD)

2026-07-29 20:30 3040

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor...

2026-07-27 20:00 4770

Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management

* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaO...

2026-07-22 21:00 4662

Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and ...

2026-07-15 08:00 4043

Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage ...

2026-07-13 08:30 3723

Insilico Medicine Releases Positive Profit Alert for the First Half of 2026

CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX...

2026-07-09 08:30 3963

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after miles...

2026-07-07 21:43 4922

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic ar...

2026-07-02 10:16 4215

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical...

2026-06-22 12:37 7723

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics

CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: ...

2026-06-17 21:00 9313

Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science

Cambridge, Mass., May 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-...

2026-05-26 21:41 11713

Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development

SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology co...

2026-05-12 20:30 4765

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study

* Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability...

2026-04-29 09:00 5293

Latest News